Takeda logo

Financial Statements and Highlights | Takeda Investor Relations

glasses laying on a book with stock options

Financial Highlights

LoadingLoading feed metadata...

Sign up for our investors newsletter

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Sign up

Recent News

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

CalendarNovember 7, 2025

New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

CalendarNovember 3, 2025

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

CalendarOctober 30, 2025

Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)

CalendarOctober 30, 2025
View More

Explore